Oral Anti−COVID-19 Medications—a Game Changer? - Frankly Speaking Ep 263

<p style="margin: 0in; font-family: Calibri; font-size: 11.0pt;"> Credits: 0.25 AMA PRA Category 1 Credit™</p> <p style="margin: 0in; font-family: Calibri; font-size: 11.0pt;">  </p> <p style="margin: 0in; font-family: Calibri; font-size: 11.0pt;"> CME/CE Information and Claim Credit: <a href= "https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-246"> https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-263</a></p> <p style="margin: 0in; font-family: Calibri; font-size: 11.0pt;">  </p> <p style="margin: 0in; font-family: Calibri; font-size: 11.0pt;"> Overview: The FDA’s recent emergency use authorization (EUA) for oral agents to treat COVID-19 means that primary care providers (PCPs) will be on the frontline of treating patients with COVID-19. Therefore, PCPs must understand who is eligible for such treatments and how to prescribe them. We will discuss the results of the recent FDA EUA for Pfizer’s Paxlovid and Merck’s molnupiravir antiviral agents and give you the information you need to confidently prescribe them.</p> <p style="margin: 0in; font-family: Calibri; font-size: 11.0pt;">  </p> <p style="margin: 0in; font-family: Calibri; font-size: 11.0pt;"> Episode resource links:</p> <ul> <li style="font-family: Calibri; font-size: 11pt;"><a href= "https://www.fda.gov/media/155054/download" target="_blank" rel= "noopener">FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR MOLNUPIRAVIR (fda.gov)</a></li> <li style="font-family: Calibri; font-size: 11pt;"><a href= "https://www.fda.gov/media/155050/download" target="_blank" rel= "noopener">FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVID (fda.gov)</a></li> </ul> <p style="margin: 0in; font-family: Calibri; font-size: 11.0pt;"> Guest: Robert A. Baldor MD, FAAFP</p> <p style="margin: 0in; font-family: Calibri; font-size: 11.0pt;">  </p> <p style="margin: 0in; font-family: Calibri; font-size: 11.0pt;"> Music Credit: Richard Onorato</p>